Hormonal
For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.
If you have severe, early-onset obesity with hyperphagia, ask your doctor about genetic testing for monogenic causes. If you have a mutation in the leptin-melanocortin pathway (leptin, POMC, PCSK1, or LEPR genes), targeted treatments like setmelanotide or metreleptin can be highly effective, resulting in significant weight loss for many patients.
Recombinant human leptin is transformative for individuals with leptin deficiency... Setmelanotide... results in substantial reduction in hunger and weight loss of ≥10% after 1 year of treatment in 80% of individuals with POMC deficiency and 45% of those with LEPR deficiency.
Why this rating
Based on clinical trials showing substantial and consistent weight loss in specific genetic subgroups.
Source
Individualised prescription of medications for treatment of obesity in adults
Samantha Hocking et al. · Reviews in Endocrine and Metabolic Disorders · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →